Warning Letters Drive Home GMP Testing Standards
This article was originally published in The Tan Sheet
Executive Summary
FDA’s recent warning letters regarding violations of supplement good manufacturing practices touched on Protica Inc.’s failure to reject out-of-specification products and Health One Pharmaceuticals’ proposal to use organoleptic testing. Vitagenic Inc. and Modern Products Inc. also received warnings.